ME00591A - Upotreba dii4 antagonista kod ishemijske pobrede ili vaskularne insuficijencije - Google Patents

Upotreba dii4 antagonista kod ishemijske pobrede ili vaskularne insuficijencije

Info

Publication number
ME00591A
ME00591A MEP-31/09A MEP3109A ME00591A ME 00591 A ME00591 A ME 00591A ME P3109 A MEP3109 A ME P3109A ME 00591 A ME00591 A ME 00591A
Authority
ME
Montenegro
Prior art keywords
ischemic
dii4
nopati
reti
occlusion
Prior art date
Application number
MEP-31/09A
Other languages
Bosnian (bs)
English (en)
Inventor
Stanley J Wiegand
Nicholas J Papadopoulos
Ivan B Lobov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ME00591B publication Critical patent/ME00591B/me
Publication of ME00591A publication Critical patent/ME00591A/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-31/09A 2006-08-07 2007-08-07 Upotreba dii4 antagonista kod ishemijske pobrede ili vaskularne insuficijencije ME00591A (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83600306P 2006-08-07 2006-08-07
PCT/US2007/017546 WO2008019144A2 (en) 2006-08-07 2007-08-07 Threapeutic methods for treating vascular eye disorders with dll4 antagonists

Publications (2)

Publication Number Publication Date
ME00591B ME00591B (me) 2011-12-20
ME00591A true ME00591A (hr) 2011-12-20

Family

ID=38904599

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-31/09A ME00591A (hr) 2006-08-07 2007-08-07 Upotreba dii4 antagonista kod ishemijske pobrede ili vaskularne insuficijencije

Country Status (32)

Country Link
US (1) US20080181893A1 (hr)
EP (1) EP2054082B1 (hr)
JP (1) JP5529536B2 (hr)
KR (1) KR101497355B1 (hr)
CN (1) CN101500605B (hr)
AU (1) AU2007281916B2 (hr)
BR (1) BRPI0716424B8 (hr)
CA (1) CA2660235C (hr)
CO (1) CO6150190A2 (hr)
CR (1) CR10627A (hr)
DK (1) DK2054082T3 (hr)
ES (1) ES2398253T3 (hr)
GT (1) GT200900029A (hr)
HR (1) HRP20130271T1 (hr)
IL (1) IL196612A (hr)
MA (1) MA30667B1 (hr)
ME (1) ME00591A (hr)
MX (1) MX2009000674A (hr)
MY (1) MY150092A (hr)
NO (1) NO341857B1 (hr)
NZ (1) NZ574794A (hr)
PL (1) PL2054082T3 (hr)
PT (1) PT2054082E (hr)
RS (1) RS52685B (hr)
RU (1) RU2429876C2 (hr)
SG (1) SG174033A1 (hr)
SI (1) SI2054082T1 (hr)
SV (1) SV2009003161A (hr)
TN (1) TN2009000036A1 (hr)
UA (1) UA95304C2 (hr)
WO (1) WO2008019144A2 (hr)
ZA (1) ZA200900337B (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20100119526A1 (en) * 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
MX2011002418A (es) * 2008-09-10 2011-04-05 Genentech Inc Metodos para inhibir la angiogenesis ocular.
EP2344536A1 (en) * 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2011008641A1 (en) 2009-07-13 2011-01-20 Beth Israel Deaconess Medical Center, Inc. Methids of modulating angiogenesis and treatment of angiogenesis-related diseases
MX336152B (es) 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
US9931199B2 (en) * 2014-05-05 2018-04-03 Roberto Gustavo ALBERTAZZI Methods and apparatus for treating keratoconus
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
WO2018094267A1 (en) * 2016-11-17 2018-05-24 Children's Medical Center Corporation Novel methods to enhance microvascular engraftment of bioengineered and primary tissues
WO2023063842A1 (ru) 2021-10-12 2023-04-20 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующая слитый белок

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
AU2006287228B2 (en) * 2005-09-01 2012-12-13 Alora Biopharma, Inc. Methods for using and identifying modulators of Delta-like 4
KR20090016762A (ko) * 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
JP2010500355A (ja) 2010-01-07
EP2054082B1 (en) 2012-12-26
CA2660235A1 (en) 2008-02-14
NO341857B1 (no) 2018-02-12
US20080181893A1 (en) 2008-07-31
DK2054082T3 (da) 2013-01-21
BRPI0716424B1 (pt) 2018-06-26
GT200900029A (es) 2009-11-17
PT2054082E (pt) 2013-03-07
MA30667B1 (fr) 2009-08-03
SI2054082T1 (sl) 2013-04-30
KR20090039823A (ko) 2009-04-22
AU2007281916B2 (en) 2012-06-28
BRPI0716424B8 (pt) 2021-05-25
WO2008019144A3 (en) 2008-03-27
PL2054082T3 (pl) 2013-05-31
ZA200900337B (en) 2009-12-30
RS52685B (sr) 2013-08-30
ME00591B (me) 2011-12-20
MY150092A (en) 2013-11-29
SV2009003161A (es) 2010-02-01
JP5529536B2 (ja) 2014-06-25
ES2398253T3 (es) 2013-03-14
BRPI0716424A2 (pt) 2014-05-20
CN101500605A (zh) 2009-08-05
HRP20130271T1 (hr) 2013-04-30
HK1137339A1 (en) 2010-07-30
UA95304C2 (ru) 2011-07-25
WO2008019144A2 (en) 2008-02-14
CO6150190A2 (es) 2010-04-20
IL196612A0 (en) 2011-08-01
NO20090984L (no) 2009-03-04
AU2007281916A1 (en) 2008-02-14
EP2054082A2 (en) 2009-05-06
NZ574794A (en) 2011-06-30
RU2429876C2 (ru) 2011-09-27
TN2009000036A1 (en) 2010-08-19
CA2660235C (en) 2015-09-22
RU2009107921A (ru) 2010-09-20
MX2009000674A (es) 2009-02-04
IL196612A (en) 2012-02-29
SG174033A1 (en) 2011-09-29
CR10627A (es) 2009-04-14
CN101500605B (zh) 2014-04-30
KR101497355B1 (ko) 2015-03-02

Similar Documents

Publication Publication Date Title
ME00591A (hr) Upotreba dii4 antagonista kod ishemijske pobrede ili vaskularne insuficijencije
Bae et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial
CA2951686C (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject
FI2765988T3 (fi) Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus
JP2015523986A5 (hr)
WO2021220061A3 (en) Heterodimer compositions and methods for the treatment of ocular disorders
Liu et al. Remote ischemic preconditioning protects against ischemic stroke in streptozotocin-induced diabetic mice via anti-inflammatory response and anti-apoptosis
Chang et al. Corneal penetration by tarantula hairs
Dumitrache Ophtalmological pathology and management of ocular disease in retinal metabolic phacomatosis
RU2575966C2 (ru) Способ лечения неоваскулярной глаукомы
CY1113840T1 (el) Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια
Uva et al. The effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma
Kayikcioglu et al. Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide
Kalina et al. Proliferative retinopathy after treatment of carotid-cavernous fistulas
DOP2009000015A (es) Uso de antagonistas de dll4 para tratar trastornos oculares vasculares
Ko et al. Visual loss after intraoral local anesthesia for the removal of circumzygomatic and circum-mandibular wires: a case report
CN107648236B (zh) 一种预防或治疗缺血/再灌注损伤的药物组合物及应用
RU2306957C1 (ru) Способ регионарной анестезии при операции ампутации нижних конечностей
RU2607356C2 (ru) Способ лечения острых нарушений кровообращения сетчатки и зрительного нерва
Omileke et al. Elucidating the Mechanisms Involved in Intracranial Pressure Elevation and Hypothermia Treatment for Ischaemic Stroke
RU2612099C1 (ru) Способ выполнения анестезиологического сопровождения офтальмологических операций
Mateshuk-Vatseba et al. Morphometric study of angioarchitectonic under the effect of opioid (experimental study)
Neovascularization What Is New in Ophthalmic Research
Bodem Vascular Lesions of the Head and Neck
RU2467719C2 (ru) Способ лечения невралгии тройничного нерва